Home » Newsletters » BioWorld Science

BioWorld Science

May 21, 2013

View Archived Issues

A groundbreaking technique to aid accurate network imaging in intact brains

Dual mTORC1/2 inhibitor shows promise as immunosuppressant in vivo

The development of probes to determine the therapeutic potential of epigenetic inhibitors

Clinical results presented for a novel cancer immunotherapy

Phase IIa studies indicate GFT-505 may reduce remnant cholesterol

Helsinn and Vifor sign agreement for netupitant/palonosetron fixed-dose combination

Bayer seeks approval for riociguat in Japan

AbbVie and Galapagos add Crohn's disease to GLPG-0634 collaboration

Novo Nordisk reports results from first phase III trial of N9-GP

FDA clears Oramed's IND to test ORMD-0801 oral insulin

Otsuka reports on regulatory and clinical developments of fiscal 2012

Curie-Cancer and Roche partner further on translational research programs

Sanofi reports topline data from pivotal phase III JAKARTA study

XenoPort ends development of arbaclofen placarbil for MS spasticity

Bydureon launched in Japan

Breakthrough therapy designation for Synageva's sebelipase alfa

Astex Therapeutics designs novel FGFR inhibitors

Scientists at GlaxoSmithKline present new agents for cancer

FDA grants orphan drug status to ibrutinib, terguride and HIRMAb-IDS

New mTOR inhibitors disclosed by Novartis

Novel cannabinoid CB2 receptor agonists synthesized at Roche

Pfizer ends phase III trial of inotuzumab ozogamicin

Sanofi divulges novel PKC-beta 2 inhibitors

FDA advisory committee sets date to review MoxDuo NDA

Reva Medical offers update on development of ReZolve and ReZolve2 scaffolds

High efficacy and long duration of a new formulation of NAG-MLP and chol-siRNAs

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...
Janssen Pharmaceutica reports new TMEM175 activators
BioWorld Science
Janssen Pharmaceutica NV has identified new endosomal/lysosomal proton channel TMEM175 activators that are potentially useful for the treatment of Parkinson’s...